Final results of the CLL14 study reveal the efficacy of 1-year venetoclax-obinutuzumab therapy for chronic lymphocytic leukemia. The combination of venetoclax (Venclexta; AbbVie/Genentech) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results